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607
Background and Purpose—Intravenous thrombolysis with alteplase is one of the few approved treatments for acute 
ischemic stroke; nevertheless, little is known about its long-term effects on survival and recovery because clinical trials 
follow-up times are limited.
Methods—Patients registered between January 2005 and December 2015, to the population-based South London Stroke 
Register of first-ever strokes. Propensity score was used to match thrombolyzed and control cases to a 1:2 ratio by 
demographical and clinical covariates. The primary outcome was survival up to 10 years using Kaplan–Meier estimates, 
Cox proportional hazards, and restricted mean survival time. Secondary outcomes included stroke recurrence and 
functional status (Barthel Index and Frenchay Activities Index scores) at 5 years.
Results—From 2052 ischemic strokes, 246 treated patients were matched to 492 controls. Median follow-up time 5.45 years 
(interquartile range, 4.56). Survival was higher in the treatment group (median, 5.72 years) compared with control group 
(4.98 years, stratified log-rank test <0.001). The number needed to treat to prevent 1 death at 5 years was 12 and 20 at 
10 years. After Cox regression analysis, thrombolysis reduced risk of mortality by 37% (hazard ratio, 0.63; 95% confidence 
interval [CI], 0.48–0.82) at 10 years; however, after introducing a multiplicative interaction term into the model, mortality 
risk reduction was 42% (hazard ratio, 0.58; 95% CI, 0.40–0.82) at 10 years for those arriving within 3 hours to the hospital. 
On average, in a 10-year period, treated patients lived 1 year longer than controls. At 5 years, thrombolysis was associated 
with independence (Barthel Index≥90; odds ratio, 3.76; 95% CI, 1.22–13.34) and increased odds of a higher Frenchay 
Activities Index (proportional odds ratio, 2.37; 95% CI, 1.16–4.91). There was no difference in stroke recurrence.
Conclusions—Thrombolysis with intravenous alteplase is associated with improved long-term survival and functional status 
after ischemic stroke.   (Stroke. 2018;49:607-613. DOI: 10.1161/STROKEAHA.117.019889.)
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Evidence from randomized controlled trials and meta-analysis shows improved functional outcomes for 
acute ischemic stroke patients receiving intravenous tissue 
thrombolysis with the recombinant tissue-type plasminogen 
activator alteplase.1–3 However, it is still unclear whether 
intravenous thrombolysis has any effect on mortality, par-
ticularly in the long-term. This has led to some concerns of 
whether the early risks associated with thrombolysis (eg, 
intracranial hemorrhage) translate into better prognosis over 
time.4 Furthermore, most of the studies that have examined 
differences in outcomes between groups have had a limited 
follow-up time (5–17). Currently, information available about 
effects on survival after intravenous thrombolysis come from 
2 randomized clinical trials and 3 observational studies.5–9 
The National Institute of Neurological Disorders and Stroke 
Recombinant Tissue Plasminogen Activator Stroke Study 
assessed mortality at 12 months, without finding any signifi-
cant difference between the 2 study arms.5 More recently, a 
study using participants from the IST-3 (Third International 
Stroke Trial) found a small reduction in 3-year mortality in 
the treatment arm which was nonsignificant for all study sub-
jects but only for those who survived the first week.6 However, 
the IST-3 trial randomized patients who did not meet current 
eligibility criteria for intravenous thrombolysis with alteplase 
in standard practice (ie, patients after 4.5 hours from stroke 
onset). Three observational studies have examined long-term 
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outcomes of intravenous alteplase; however, 27,8 are limited by 
the lack of a comparison group. The third study,9 and the only 
other propensity score-matched study on intravenous alteplase 
found a 34% decrease in mortality for treated stroke patients 
in Denmark. However, this study had a limited median follow-
up of 1.4 years and did not examine differences in activities of 
daily living between groups.
In this study, we use a propensity score-matched cohort 
study design to determine whether thrombolysis with intrave-
nous alteplase, as given in standard daily clinical practice in 
the United Kingdom,10 improves long-term survival up to 10 
years after an acute ischemic stroke. Propensity score methods 
are tools for the analysis of observational studies that allow 
reducing the effect of the confounding that can occur because 
differences in the distribution of baseline characteristics and 
allow to replicate the measures of effect commonly reported 
in randomized clinical trials.11 As secondary outcomes, we 
examine whether the benefits in functional status, as assessed 
by the Barthel Index (BI) and Frenchay Activities Index (FAI), 
persist at 5 years after a stroke, as well as if stroke recurrence 
is affected by intravenous alteplase.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Study Design
The South London Stroke Register (SLSR) is an ongoing, prospec-
tive, population-based, stroke register. The SLSR started in January 
1995 and documents all first-ever confirmed strokes (according to the 
World Health Organization Criteria12) in patients of all ages for an 
inner area of South London that includes 22 electoral wards in the 
Boroughs of Lambeth and Southwark.13 The total source population 
of the SLSR area is 357 308 inhabitants, as estimated in the 2011 
census and comprises a distinctly multiethnic population with a sig-
nificant proportion of black Caribbean and African residents.14
Case Ascertainment
All patients with a suspected diagnosis of first-ever stroke docu-
mented from hospital- and community-based sources were inves-
tigated for study eligibility.12 Completeness of case ascertainment 
has been estimated at 88% by a multinomial logit capture-recapture 
model using the methods described elsewhere.15 A more thorough 
discussion of the methods used to maximize completeness of case 
ascertainment is available elsewhere.12,16
Data Collection
Specially trained study nurses and field workers collected all data 
prospectively. Patients were examined within 48 hours of referral to 
SLSR when possible.12 A study stroke physician verified the diag-
nosis of stroke and classified the cases according to the modified 
TOAST (Trial of ORG 10172 in Acute Stroke Treatment)17 and the 
Oxfordshire Community Stroke Project subtype.18 The Oxfordshire 
Community Stroke Project subtype, which was used to calculate the 
propensity score, consists of 4 defined subgroups total anterior circu-
lation infarcts, partial anterior circulation infarcts, lacunar infarcts, 
and posterior circulation infarcts.
Age at stroke was calculated as the difference between the date of 
birth and date of symptoms onset; ethnicity was self-reported by the 
patient and then collated into 1 of the 3 main categories according to 
the UK 2001 census (White, Black, and Other).13
Vascular risk factors before stroke (self-reported and from medi-
cal notes) were collected, including smoking, hypertension, diabetes 
mellitus, atrial fibrillation, ischemic heart disease (angina pectoris or 
myocardial infarction), peripheral vascular disease, and history of 
transient ischemic attack. Information on thrombolysis was collected 
from medical charts from 2005 onwards. The window for thromboly-
sis with intravenous alteplase was up to 3 hours after symptoms’ onset 
at the start of the study period and then extended up to 4.5 hours from 
2009 onwards.
The BI19 was used to assess functional status previous to stroke as 
well as at each follow-up visit. A cutoff of BI≥90 was used to reflect 
functional independence.20 The National Institutes of Health Stroke 
Scale (NIHSS) score was used to assess stroke severity21 during the 
acute phase. The degree of neurological deficit was classified accord-
ing to the total NIHSS score as follows minor (NIHSS, 1–4), moder-
ate (5–15), moderate-severe (16–20), and severe (≥21). The FAI is a 
frequently used measurement of Extended Activities of Daily Living 
in stroke and was assessed by trained fieldworker during follow-up 
visits.22 Follow-up visits were performed at 3 months, 1 year, and 
annually thereafter. Survival was ascertained by follow-up, which 
included contacting next of kin if the participant was unreachable, 
and by checking with the office of National Statistics. Because the 
registration of deaths in the United Kingdom is complete, all patients 
with no death record at the day of censoring were assumed to be alive.
Study Population
The study included patients recruited into the SLSR from 2005 to 
2015, inclusive. Survival time was censored at the December 31, 
2015. All patients receiving intravenous thrombolysis with complete 
data for matching variables (see below) were included in the analysis. 
None of the participants in this study were treated with intra-arterial 
thrombolysis or mechanical clot retrieval.
Ethical Approval
The study was approved by the ethics committees of Guy’s and St 
Thomas’ Hospital Trust, King’s College Hospital, Queen’s Square, 
and Westminster Hospital. Informed consent from patients or assent 
from next of kin was obtained for all participants for their inclusion 
into the South London Stroke Register.
Propensity Score Matching
Propensity scores were calculated for each patient based on a multi-
variable logistic regression model. This model included demographic 
variables (age, sex, and ethnicity), prestroke number of vascular 
risk factors, functional status previous to stroke (BI), stroke severity 
(NIHSS), stroke Oxfordshire Community Stroke Project subtype,23 
and year of stroke. Figure I in the online-only Data Supplement shows 
the substantial overlap in propensity score distributions between both 
groups; this suggests a large area of common support for the eligible 
participants. We matched treated participants with controls in a 1:2 
ratio using a greedy nearest neighbor method.24 Figure 1 presents the 
flowchart of participant selection and propensity score-matched set 
construction. The overall quality of the matched sample was assessed 
by comparing the standardized difference of means and the ratio of 
the variances between the propensity scores of both groups as well 
as by graphically inspecting the propensity scores between groups. 
Furthermore, we evaluated the balance between individual covariates 
between groups in the matched sample.
Statistical Analysis
Descriptive data are expressed in percentages, mean±SD or median 
and interquartile range (IQR) as appropriate. The primary outcome of 
this study was survival up to 10 years after the date of first-ever acute 
ischemic stroke; we report Kaplan–Meier survival estimates and the 
difference between survival curves tested using the log-rank test 
stratified to matched sets. We obtained the adjusted hazard ratio (HR) 
from a Cox regression model of proportional hazards with robust 
variance estimator. The Cox model was developed by iteratively add-
ing clinical relevant variables to a model including only treatment 
arm (ie, treated or control) regressed by the propensity score, and 
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used a log-likelihood test to evaluate whether the addition of the new 
predictor improved the fit of the previous model. To examine whether 
onset-to-arrival time modified the effect of alteplase, we then tested 
if a multiplicative interaction term between treatment with alteplase 
and arrival within 3 hours further improved the fit our model. Because 
we expected, based on the reviewed literature,6 that the proportional-
ity of the hazards assumption would be violated, we further assessed 
survival time after stroke by comparing the restricted mean survival 
time (RMST) between groups. We then adjusted the RMST for the 
same covariates used in the Cox model with an analysis of covari-
ance.25 A similar method was used to examine the difference in stroke 
recurrence between groups. Independence at 5-year BI (≥90) and 
FAI scores at 5-year follow-up were compared between groups and 
adjusted for age, sex, ethnicity, prestroke BI, acute phase NIHSS, and 
stroke subtype by performing multiple regression analysis. We con-
ducted a sensitivity analysis with multiple imputation to examine how 
robust our results were to missing data. All analyses were performed 
using R26 version 3.2.2 (2015) on R-Studio27 version 1.0.136.
Results
A total of 2052 patients with their first-ever ischemic stroke 
were recruited between the January 1, 2005 and the December 
31, 2015; 285 (13.9%) of these patients received intravenous 
thrombolysis with alteplase. From the total recruited, 334 
(16.3%) had missing data for at least 1 of the variables used to 
calculate the propensity score and thus had to be excluded. Of 
the 1718 remaining subjects, we paired 246 treated patients with 
492 controls (Figure 1). None of these patients received intra-
arterial thrombolysis or underwent thrombectomy. Measures of 
balance diagnosis28 indicated that the sample was adequately 
matched, with a standardized difference of the means of pro-
pensity scores between groups of 0.14 (good balance<0.25) 
and a ratio of variances of propensity scores of 1.27 (good bal-
ance between 0.5–2). A comparison of the baseline character-
istics further supports the good balance of our matched sample 
(Table 1; Table I in the online-only Data Supplement).
The median follow-up time was 5.45 years (IQR=4.56; 
range, 0–10 years), and a total of 344 (46.6%) patients died 
during the study period.
Primary Outcome: Survival up to 10 Years
The Kaplan–Meier estimate shows a higher survival for patients 
treated with intravenous alteplase than for those in the control 
group at 5 and 10 years (Figure 2; log-rank test stratified by sets 
<0.001 for both). The median survival time for the treated group 
was 5.72 and 4.98 years for the control group. The absolute risk 
reduction at 5 years was 8.33% (95% confidence interval [CI], 
8.19–8.47; number needed to treat, 12) and 5.07% (95% CI, 
4.92–5.22) at 10 years (number needed to treat, 20).
The unadjusted HR shows a 19% (HR, 0.81; 95% CI, 0.70–
0.92) and 28% (HR, 0.72; 95% CI, 0.57–0.91) decrease in 
mortality risk for the treated group at 5 and 10 years, respec-
tively. After adjusting for age, prestroke BI, prestroke use of 
anticoagulants, NIHSS during the acute phase, and poststroke 
treatment with antiplatelets, thrombolysis with intravenous 
alteplase was associated with a 28% (HR, 0.72; 95% CI, 0.60–
0.87) decrease in mortality at 5 years and 37% (HR, 0.63; 95% 
CI, 0.48–0.82) at 10 years (Table II in the online-only Data 
Supplement). After including a multiplicative interaction term 
between thrombolysis with intravenous alteplase and arrival 
to the hospital within 3 hours, mortality reduction for those 
treated earlier was 32% (HR, 0.67; 95% CI, 0.52–0.88) at 5 
years and 42% (HR, 0.58; 95% CI, 0.40–0.82) at 10 years 
(Table 2; Figure II in the online-only Data Supplement).
Visual and formal testing revealed hazards to be nonpro-
portional (P<0.0001) for the whole duration of the follow-up. 
To account for this, we calculated the RMST for each group. 
Patients receiving intravenous alteplase had an RMST of 
6.06 years, whereas the control group RMST was 5.18 years. 
Figure 1. Data attrition flowchart.
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The estimated difference in RMST between groups was 0.88 
years (95% CI, 0.18–1.59; P=0.015) over a 10-year follow-
up period. After adjustment for the same covariates used in 
the Cox proportional hazards model, the estimated difference 
between RMST was 1.04 years (95% CI, 0.17–1.91; P=0.02).
Secondary Outcomes: Functional Status at 5 Years
Thrombolysis with intravenous alteplase was associated with 
improved functional status. After adjusting for age, sex, eth-
nicity, prestroke BI, acute phase NIHSS, and stroke subtype, 
treatment was significantly associated with independence 
(BI≥90) at discharge (odds ratio, 2.01; 95% CI, 1.27–3.20) 
and at 5 years (odds ratio, 3.76; 95% CI, 1.22–13.34). 
Intravenous alteplase was also associated with increased odds 
of higher FAI score (proportional odds ratio, 2.37; 95% CI, 
1.16–4.91) at 5 years. There was no difference in stroke recur-
rence between groups.
Discussion
Key Findings
In this study, which to our knowledge has the longest median 
follow-up time in the published literature, we found evidence in 
a real-world setting of reduced mortality after thrombolysis with 
intravenous alteplase. Our findings show that on average, and 
over a 10-year period, a patient treated with thrombolysis lives 
around 1 year longer than a similar nonthrombolyzed patient after 
adjustment for age, sex, prestroke BI, prestroke treatment with 
anticoagulants, acute phase NIHSS score, and poststroke treat-
ment with antiplatelets. Our data shows that the number needed 
to treat to prevent 1 death in 5 years is equal to 12 patients and 
20 to prevent 1 death at 10 years. These results complement and 
expand on previous data reported by the Danish Stroke Register9 
and the subanalysis of the IST-3 trial6 by demonstrating that the 
Table 1. Baseline Characteristics
 
Alteplase 
(n=246)
Controls 
(n=492)
P 
Value
Male, n (%) 123 (50.0) 235 (47.8) 0.621
Age, mean (SD) 68.0 (15.9) 69.4 (16.4) 0.241
Ethnicity   0.984
  White, n (%) 159 (64.6) 315 (64.0)
  Black, n (%) 67 (27.2) 137 (27.9)
  Other, n (%) 20 (8.1) 40 (8.1)
No. of risk factors, median (IQR) 2 (2) 2 (2) 0.641
Prestroke Barthel Index, mean (SD) 19.1 (2.6) 19.1 (2.8) 0.891
NIHSS, median (IQR) 10 (11) 9 (12) 0.111
Stroke subtype   0.815
  TACI, n (%) 69 (28.1) 123 (25.0)
  PACI, n (%) 115 (46.8) 245 (49.8)
  LACI, n (%) 34 (13.8) 70 (14.2)
  POCI, n (%) 28 (11.4) 54 (11.0)
TOAST classification   0.287
  LAA, n (%) 39 (15.9) 56 (11.38)
  Cardioembolic, n (%) 76 (30.9) 137 (27.9)
  SVO, n (%) 37 (15.0) 85 (17.3)
  Other, n (%) 3 (1.2) 10 (2.0)
  Undetermined, n (%) 91 (37.0) 204 (41.5)
IQR indicates interquartile range; LAA, large artery atherothrombotic; LACI, 
lacunar infarction; NIHSS, National Institutes of Health Stroke Scale; PACI, partial 
anterior circulation infarction; POCI, posterior circulation infarction; SVO, small 
vessel occlusion; TACI, total anterior circulation infarction; and TOAST, Trial of 
ORG in Acute Stroke Treatment.
Figure 2. Survival curves for intravenous alteplase treated group 
(darker) and control group (lighter) groups. Median follow-up time 
5.45 years. Median survival for treated group 5.72 years. Median 
survival for control group 4.98 years. Stratified log-rank test: 
P<0.001.
Table 2. Multivariable Cox Regression on Survival Including 
Interaction Term
Thrombolysis
  Arrival within 
3 h
0.67 0.52–0.88 0.004 0.58 0.40–82 0.002
  Arrival after 
3 h
0.86 0.67–1.11 0.247 1.15 0.55–2.43 0.154
Age, y 1.03 1.02–1.03 <0.001 1.05 1.04–1.06 <0.001
Barthel Index 
(point)
0.94 0.91–0.98 0.003 0.94 0.91–0.98 0.003
Prestroke 
anticoagulants 
(yes)
1.62 1.09–2.40 0.017 1.54 0.91–2.61 0.106
NIHSS (point) 1.05 1.03–1.07 <0.001 1.06 1.04–1.08 <0.001
Poststroke 
antiplatelets (yes)
0.58 0.48–0.70 <0.001 0.48 0.37–0.63 <0.001
Propensity score 
(point)
0.43 0.16–1.16 0.09 1.15 0.54–2.43 0.710
Hazard ratios are adjusted by the variables shown in the table. NIHSS 
indicates National Institutes of Health Stroke Scale.
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benefits of thrombolysis in survival are appreciable even after 
a period as long as 10 years poststroke and the improved func-
tional outcomes are still perceivable at 5 years. Furthermore, 
our findings also suggest that the observed benefit in survival is 
seemingly driven by older patients and those with NIHSS≥16 
(moderate-severe and severe strokes; Figure 3).
Compared with the Danish nationwide register study,9 our 
study had a slightly older mean age (treated, controls; SLSR, 
68.0, 69.4 versus Danish Register, 65.8, 66.5) a significantly 
longer median follow-up time (5.45 versus 1.4 years), and con-
sequently a higher proportion of deaths (46.6% compared with 
14.7%). Furthermore, our study included a higher proportion 
of moderate (48.4%, 56.7% versus 33.8%, 33.9%) and severe 
strokes (16.7%, 15.2% versus 7.7%, 7.9%), a comparable 
proportion of moderate-severe strokes (17.5%, 12.2% versus 
14.9%, 15.0%) and significantly fewer minor strokes (17.5%, 
15.9% versus 41.4%, 41.5%) according to the scale used by 
each study (NIHSS versus Scandinavian Stroke Scale).The 
median stroke severity was also slightly higher in our cohort 
(10, 9 versus 8, 8, converted from Scandinavian Stroke Scale 
to NIHSS using the formula found elsewhere29). Our popu-
lation also had a higher prevalence of hypertension (64.2%, 
65.7% versus 50.9%, 47.8%), and diabetes mellitus (20.3%, 
21.1% versus 9.6%, 12.6%; Table I in the online-only Data 
Supplement). Additionally, our population was comprised of 
first-ever strokes only. Despite these differences our adjusted 
HR for the whole duration of the study, without time to arrival 
interaction term, are similar (0.63 [95% CI, 0.48–0.82] versus 
0.66 [95% CI, 0.49–0.88]) suggesting the benefits from intra-
venous alteplase are generalizable across populations.
The precise mechanism or mechanisms by which throm-
bolysis improves survival are unknown, although there is an 
evidence thrombolysis decreases infarct size30 and reduces the 
risk of readmissions because of pneumonia,31 although the 
impact on other factors is still unclear. Nevertheless, previous 
studies have shown that good functional outcomes in the short 
term (ie, within 6 months) are associated with improved long-
term survival, in part because of fewer complications and more 
independence.9,32,33 In our cohort, patients in the treatment 
group had overall better scores in BI and FAI even at 5-years 
poststroke after adjustment, further suggesting the association 
between functional status and survival. Furthermore, better 
BI scores have been strongly associated with quality of life34 
which means that the improved survival seen with alteplase is 
also accompanied by improved quality of life.
Strengths and Weaknesses
The main strengths of this study include a long follow-up time 
(up to 10 years, median 5.45 year), a per protocol, prospectively 
collected data set with a wide range of variables that allowed 
a good balance in baseline variables between groups, an ethni-
cally diverse study population of a well-defined area with a 
near-complete recording of deaths, achieved by linking with 
the Office of National Statistics and follow-up by the register 
fieldworkers. Additionally, we provide the adjusted difference 
in RMST, a summary statistic which has been shown to better 
estimate time-to-event than the HR when the proportionality 
Figure 3. Forest plot showing the point 
estimates incidence rate ratio (IRR) with 
their respective CI for mortality per 100 
person-year stratified by age and National 
Institutes of Health Stroke Scale (NIHSS) 
group. Median (interquartile range) 
NIHSS<16 group was 7 (5); NIHSS≥16 
group was 21 (6). CI indicates confidence 
interval.
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of the hazards assumption is not met.25 Furthermore, the differ-
ence in RMST can be straightforwardly interpreted in clinical 
settings by both the treating physician, the patients and their 
next of kin. The main limitation of this study lies in its design as 
an observational rather than experimental study. However, we 
have used propensity score matching to reduce potential bias 
and strengthen our reported effect estimates.35 Additionally, 
we matched every treated patient with a similar control and 
included the calculated propensity score into the multivariable 
analysis (double propensity score adjustment), thus reduc-
ing as much as possible confounding because of incomplete 
matching and residual confounding. Another limitation is the 
effect of missing data in the propensity score matching as well 
as the analysis. This limitation is common to all studies, par-
ticularly those with long follow-up times. Nevertheless, a sen-
sitivity analysis demonstrated that our results were robust to 
the influence of missing data. Additional limitations include 
that the SLSR does not collect information about the time of 
thrombolysis and that the modified Rankin Scale score is not 
available for follow-ups before 2014. However, although it is 
not possible for us to calculate the onset-to-treatment time, we 
have used onset-to-arrival times as a proxy instead; this value 
is not only correlated with the time from onset to treatment, 
but also is available for nontreated patients, and thus, it could 
be fitted into the Cox model. Although we do not have enough 
data on the modified Rankin Scale score at 5 years, we have 
used the BI with a threshold of ≥90 to define independence; 
using this cutoff point has been shown to be comparable to a 
modified Rankin Scale score of ≤220.
Implications for Clinical Practice
Despite the amount of evidence provided by clinical trials 
demonstrating that thrombolysis with alteplase improves func-
tional outcomes in ischemic strokes at 1 year, the adoption of 
thrombolysis has been slow by many centers. Although the rea-
sons for this are multifactorial, including concerns with regards 
to costs and required experience, one of the main arguments 
has been the uncertainty on whether the risks associated with 
thrombolysis indeed result in better outcomes in the long-term. 
In this study, we have shown that not only patients treated with 
intravenous alteplase have better BI and FAI scores at 5 years 
but that they also experience a lower mortality risk, with rela-
tively low numbers needed to treat to prevent a death at 10 
years. Furthermore, this study was done using data from a real-
world setting from a diverse population, and thus our results 
are generalizable. These findings should provide much-needed 
evidence to reassure treating clinicians and patients about the 
long-term benefits of intravenous thrombolysis therapy with 
alteplase following currently accepted guidelines.
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Supplementary Table I. Comparison of baseline characteristics between treated and control participants 
 
Original Sample   Matched Sample  
Thrombolysis 
(n=246) 
Controls 
(n=1472) 
Standardized 
Difference* 
P  Thrombolysis 
(n=246) 
Controls 
(n=492) 
Standardized 
Difference* 
p 
DEMOGRAPHICS          
Male, n (%) 123 (50.0) 795 (54.0) 0.08 0.272  123 (50.0) 235 (47.8) 0.05 0.621 
Age, mean (sd) 68.0 (15.9) 70.0 (15.1) 0.11 0.111  68.0 (15.9) 69.4 (16.4) 0.09 0.241 
Age Categories    0.224     0.306 
 <45, n (%) 25 (10.16) 93 (6.32) 0.15   25 (10.16) 41 (8.33) 0.06  
45-64, n (%) 72 (29.27) 427 (29.01) 0.01   72 (29.27) 144 (29.27) 0.00  
65-74, n (%) 52 (21.14) 331 (22.49) 0.03   52 (21.14) 92 (18.7) 0.06  
75-84, n (%) 64 (26.02) 384 (26.09) 0.00   64 (26.02) 119 (24.19) 0.04  
≥ 85, n (%) 33 (13.41) 237 (16.1) 0.07   33 (13.41) 96 (19.51) 0.15  
Ethnicity    0.756     0.984 
White, n (%) 159 (64.6) 924 (62.8) 0.03   159 (64.6) 315 (64.0) 0.01  
Black, n (%) 67 (27.2) 435 (29.6) 0.05   67 (27.2) 137 (27.9) 0.01  
Other, n (%) 20 (8.1) 113 (16.1) 0.01   20 (8.1) 40 (8.1) 0.00  
 
PRE- STROKE RISK 
FACTORS 
         
Hypertension, n (%) 158 (64.2) 1023 (69.5) 0.12 0.100  158 (64.2) 323 (65.7) 0.04 0.628 
Diabetes, n (%) 50 (20.3) 351 (23.9) 0.08 0.268  50 (20.3) 104 (21.1) 0.02 0.851 
Cholesterol, n (%) 117 (47.6) 665 (45.2) 0.06 0.471  117 (47.6) 232 (47.2) 0.08 0.979 
A Fib, n (%) 41 (16.7) 261 (17.7) 0.01 0.913  41 (16.7) 101 (20.5) 0.09 0.296 
TIA, n (%) 25 (10.2) 149 (10.1) 0.07 0.015  25 (10.2) 44 (8.9) 0.07 0.668 
IHD, n (%) 25 (10.2) 170 (11.6) 0.04 0.003  25 (10.2) 53 (11.4) 0.02 0.878 
Smoker, n (%) 27 (11.0) 332 (22.6) 0.04 0.962  27 (11.0) 56 (11.4) 0.08 0.860 
Num. of Risk Factors          
Median (IQR) 2 (2) 2 (2) 0.15 0.032  2 (2) 2 (2) 0.04 0.641 
Num RF Categories    0.067     0.985 
None, n (%) 58 (23.6) 237 (16.1) 0.20   58 (23.6) 111 (22.6) 0.02  
1, n (%) 51 (20.7) 342 (23.2) 0.06   51 (20.7) 100 (20.3) 0.01  
2, n (%) 66 (26.8) 404 (27.5) 0.01   66 (26.8) 133 (27.0) 0.00  
3, n (%) 51 (20.7) 342 (23.2) 0.06   51 (20.7) 102 (20.7) 0.00  
≥4, n (%) 20 (8.1) 147 (10.0) 0.06   20 (8.1) 46 (9.4) 0.04  
PRE-STROKE 
FUNCTIONAL 
STATUS 
         
Barthel, mean (sd) 19.1 (2.6) 18.8 (3.4) 0.12 0.044  19.1 (2.6) 19.1 (2.8) 0.01 0.891 
 
STROKE SEVERITY 
         
NIHSS, median (IQR) 10 (11) 5 (7) 0.61 <0.001  10 (11) 9 (12) 0.07 0.111 
Neurological Deficit †	    <0.001     0.118 
Minor, n (%) 43 (17.5) 700 (47.6) 0.62   43 (17.5) 78 (15.9) 0.04  
Moderate, n (%) 119 (48.4) 570 (38.7) 0.20   119 (48.4) 279 (56.7) 0.16  
Mod-Severe, n (%) 43 (17.5) 86 (5.8) 0.45   43 (17.5) 60 (12.2) 0.15  
Severe, n (%) 41 (16.7) 116 (7.9) 0.31   41 (16.7) 75 (15.2) 0.04  
Stroke subtype    <0.001     0.815 
TACI, n (%) 69 (28.1) 179 (12.2) 0.46   69 (28.1) 123 (25.0) 0.07  
PACI, n (%) 115 (46.8) 589 (40.0) 0.14   115 (46.8) 245 (49.8) 0.06  
LACI, n (%) 34 (13.8) 449 (30.5) 0.37   34 (13.8) 70 (14.2) 0.01  
POCI, n (%) 28 (11.4) 255 (17.3) 0.16   28 (11.4) 54 (11.0) 0.01  
 
 
TOAST Classification 
    
 
<0.001 
     
 
0.287 
LAA, n (%) 39 (15.9) 156 (10.6) 0.17   39 (15.9) 56 (11.38) 0.13  
CE, n (%) 76 (30.9) 326 (22.2) 0.21   76 (30.9) 137 (27.9) 0.07  
SVO, n (%) 37 (15.0) 493 (33.5) 0.40   37 (15.0) 85 (17.3) 0.06  
Other, n (%) 3 (1.2) 21 (1.4) 0.02   3 (1.2) 10 (2.0) 0.06  
Und, n (%) 91 (37.0) 476 (32.3) 0.10   91 (37.0) 204 (41.5) 0.09  
 
YEAR OF STROKE 
    
<0.001 
     
0.999 
2005, n (%) 6 (2.4) 215 (14.6) 0.37   6 (2.4) 9 (1.8) 0.04  
2006, n (%) 12 (4.9) 159 (10.8) 0.20   12 (4.9) 30 (6.1) 0.05  
2007, n (%) 23 (9.4) 154 (10.5) 0.04   23 (9.4) 46 (9.35) 0.00  
2008, n (%) 32 (13.0) 127 (8.6) 0.15   32 (13.0) 64 (13.01) 0.00  
2009, n (%) 26 (10.6) 147 (10.0) 0.02   26 (10.6) 59 (12.0) 0.05  
2010, n (%) 34 (13.8) 141 (9.6) 0.14   34 (13.8) 68 (13.8) 0.00  
2011, n (%) 19 (7.7) 126 (7.9) 0.03   19 (7.7) 37 (7.5) 0.00  
2012, n (%) 30 (12.2) 116 (7.9) 0.16   30 (12.2) 52 (10.6) 0.05  
2013, n (%) 25 (10.2) 101 (6.9) 0.13   25 (10.2) 46 (9.4) 0.03  
2014, n (%) 25 (10.2) 83 (5.6) 0.19   25 (10.2) 51 (10.4) 0.00  
2015, n (%) 14 (5.7) 103 (7) 0.05   14 (5.7) 30 (6.1) 0.02  
 * A standardized difference (of means) < 0.25 indicates good balance between groups. 
† Based on total NIHSS score: Minor (1 to 4), moderate (5 to 15), moderate to severe (16 to 20), severe (≥20)	
A fib, atrial fibrillation; NIHSS, National Institute of Health Stroke Scale; TACI, total anterior circulation infarction; PACI, partial 
anterior circulation infarction; LACI, lacunar infarction; POCI, posterior circulation infarction; LAA, Large artery atherothrombotic; 
CE, cardioembolic; SVO, small vessel occlusion; Und, undetermined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary	Table	II. Multivariable Cox Regression on survival 
  Survival at 5 years Survival at 10 years 
Predictor  Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p-value 
Thrombolysis (yes)  0.72 0.60-0.87 0.003 0.63 0.48-0.82 <0.001 
Age (years)  1.03 1.02-1.03 <0.001 1.05 1.04-1.06 <0.001 
Barthel Index (point)  0.95 0.92-0.99 0.008 0.95 0.92-0.98 0.003 
Pre-stroke anticoagulants (yes)  1.93 1.40-2.67 <0.001 1.85 1.25-2.73 <0.001 
NIHSS (point)  1.05 1.04-1.07 <0.001 1.07 1.05-1.09 <0.001 
Post-stroke antiplatelets (yes)  0.55 0.46-0.64 <0.001 0.44 0.35-0.56 0.006 
Propensity score (point)  0.46 0.26-1.47 0.081 0.50 0.15-1.61 0.650 
Hazard ratios are adjusted by the variables shown in the table. 
NIHSS, national institute of health stroke scale. 
 
 
Supplementary Figure I. Distribution of propensity scores between the treated and controls 
group. An overlap between both distributions suggests good balance between groups. 
 
 
 
 
 
 Supplementary Figure II. Forest plot showing the point estimates (Hazard Ratios) with their 
respective confidence interval for the Cox model on survival at 10 years. 
